Vertex Pharmaceuticals’ global revenue has almost doubled since 2019

Trikafta was approved in the U.S. in late 2019, and then in Canada and other countries shortly after. It costs about $350,000 per patient per year in Canada and has quickly become Vertex's most lucrative pharmaceutical product. (In billions of U.S. dollars)